The deadline for the first step of Health Canada's new risk evaluation for the presence of N-nitrosamine impurities in Canadian human pharmaceutical, biological and radiopharmaceutical products is fast approaching. This new Health Canada requirement for all Market Authorization Holders (MAHs) of Canadian human pharmaceuticals, biologicals and radiopharmaceuticals drug products was originally announced in October 2019with [...]
